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Abstract: The use of gas chromatography–mass spectrometry (GC–MS) in fo-
rensic analysis is increasing. To exploit fully the capabilities of MS, labeled 
standards, that can be used to improve the performance of the quantitative ana-
lysis, and to increase accuracy and precision, are required. A series of deute-
rated internal standards, corresponding to the 2C-series of phenethylamine 
derivatives, including 4-bromo-2,5-dimethoxyphenethylamine-d6 (2C-B), 4-chlo-
ro-2,5-dimethoxyphenethylamine-d6 (2C-C), 4-iodo-2,5-dimethoxy-phenethyl-
amine-d6 (2C-I), 4-ethylthio-2,5-dimethoxy-phenethylamine-d6 (2C-T-2) and 
2,5-dimethoxy-4-n-propylthiophenethylamine-d6 (2C-T-7), were synthesized. 
These deuterated compounds were used to analyze for the corresponding un-
labeled compounds in urine. The analysis was performed using GC–MS, with 
the selected ion monitoring (SIM) technique, whereby good results were achieved. 
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INTRODUCTION 
The increased availability of the 2C-series of phenethylamine derivatives on 
the illicit market has become a serious social problem.1 Shulgin et al., in their 
publication, Phenethylamines I have Known and Loved (PiHKAL), documented 
179 phenethylamine derivatives, including 3,4-methylenedioxymethamphetamine 
(MDMA), mescaline, 2C-B, 2C-C, 2C-I, 2C-T-2 and 2C-T-7. They also descryb-
ed relevant synthetic procedures.2 Phenethylamine derivatives are increasingly 
abused psychoactive drugs, the abuse of which is well documented.3–8 The series 
of homologous designer drugs continues to be explored and their widespread 
consumption has led to increasing number of reports of abuse and intoxication. 
The abuse of psychoactive drugs from the phenylethylamine and phenylisopro-
pylamine groups has become a very serious social problem in Taiwan over the 
last decade.9–22 
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Unknown drugs are typically detected and identified by gas chromatogra-
phy–mass spectrometry (GC–MS) because this approach is highly sensitive and 
can separate organic compounds in complex mixtures.23–26 The compounds are 
often derivatized on the amine to yield more specific fragmentation information. 
This process seriously influences the ability to detect novel amphetamine con-
trolled substance analogs.27,28 Many studies have addressed the preparation of 
deuterium-labeled control drugs as internal standards for GC–MS analysis.29–39 
The synthetic routes to 2C-C-d6, 2C-B-d6, 2C-I-d6, 2C-T-2-d6 and 2C-T-7-d6 
have been described elsewhere.31 The present investigation explores the appli-
cations of 2C-C-d6, 2C-B-d6, 2C-I-d6, 2C-T-2-d6 and 2C-T-7-d6 as internal standards. 
EXPERIMENTAL 
Reagents 
Methanol and ethyl acetate (EA) were purchased from Mallinckrodt (Paris, KY, USA). 
Trifluoroacetic anhydride was purchased from Fluka (Buchs, Switzerland). Stock solutions of 
the analytes (100 µg mL-1) were prepared in methanol. Subsequent working solutions of cali-
bration samples were prepared by diluting the stock solutions with blank urine. An internal stan-
dard (IS) solution of 2C-C-d6, 2C-B-d6, 2C-I-d6, 2C-T-2-d6 and 2C-T-7-d6, each at 20 µg mL-1, 
was prepared in methanol. The preparation of 2C-B-d6, 2C-C-d6, 2C-I-d6, 2C-T-2-d6 and 2C- 
-T-7-d6 has been described elsewhere.31 The structures of 2C-B-d6, 2C-C-d6, 2C-I-d6, 2C-T- 
-2-d6 and 2C-T-7-d6.are presented in Fig. 1. 
 
Fig. 1. The structures of 2C-B-d6, 2C-C-d6, 2C-I-d6, 2C-T-2-d6 and 2C-T-7-d6. 
Procedure 
Blank urine samples, which had been collected from volunteer laboratory personnel, 
were used for the development of the method. Blank urine samples were spiked with appro-
priate amounts of analytes at concentrations of 0, 50, 100, 500, 1000 and 2000 ng mL-1 to 
prepare calibration curves. Samples were maintained in the refrigerator at 4 °C until analysis. 
Instrumentation 
A Hewlett Packard 6890 gas chromatograph was coupled to a Hewlett Packard 5973 qua-
drupole mass spectrometer under EI conditions. Injection was performed in the splitless mode. 
The flow rate of the carrier gas (He) was 0.60 mL min-1. An HP-5MS column (12.5 m×0.20 mm 
ID, 0.33 µm film thickness; Agilent Technologies, Palo Alto, CA, USA) was used. The in-
jection port temperature was maintained at 250 °C. The GC oven temperature program started 
at 70 °C, which was maintained for 0.5 min, and then increased at 30 °C min-1 to 255 °C,   DIMETHOXYPHENETHYLAMINE DERIVATIVES IN URINE  1225 
which was maintained for 0.5 min. One µL was injected for GC–MS analysis in the full scan mo-
nitoring mode. The total analysis time was 12 min per sample with a solvent delay of 3.0 min. 
The transfer line temperature and MS source temperature were 280 and 230 °C, respectively. 
The electron energy of the MS was set to 70 eV. Full scan mass spectra of analytes and their 
deuterium analogs were collected in the m/z range 50–450 at a scan rate of 3.62 scan/s. The 
data were collected using Hewlett-Packard ChemStation software. 
Sample preparation 
To a clean 12–mL screw-cap glass tube was added 2.0 mL of urine sample and 50 µL of 
IS solution. The mixture was alkalinized with 2.0 mL of 1.0 M NaOH, and extracted with 3.0 mL 
of EA after vortexing and subsequent centrifugation at 3000 rpm for 5 min. The organic layer 
was carefully transferred to a clean tube. The mixture was evaporated to dryness under a 
stream of nitrogen gas at 50–60 °C. The dried extract was dissolved in 50 µL of EA and 
derivatized with 50 µL of trifluoroacetic anhydride for 30 min at 60 °C. The samples were 
then cooled to room temperature, evaporated to dryness, and reconstituted with 50 µL of EA. 
One µL was injected for GC–MS analysis. 
RESULTS AND DISCUSSION 
The total ion current chromatogram (monitored in the full scan mode) of five 
phenethylamine designer drugs and four structurally related sympathomimetic ami-
nes [amphetamine (A, AMP), methamphetamine (MA), 3,4-methylenedioxyam-
phetamine (MDA), and MDMA] are presented in Fig. 2. All compounds were 
chromatographically well separated. The retention times of the drugs and their 
deuterated analogues are given in Table I. Although the retention times according 
to the GCs of five sets of labeled and unlabeled compounds vary very little (0.01 
min), the selected ion monitoring (SIM) technique discriminates the labeled and 
unlabeled compounds. Therefore, these deuterium-labeled compounds have the 
potential to be used as internal standards in GC–MS analysis. The [M]+ of the 
labeled and unlabeled compounds did not overlap each other and no interference 
from the urine samples was observed. Accordingly, the 14 [M]+ were monitored 
using GC–MS with a SIM. The SIM chromatogram was obtained from 2.0 mL of 
urine sample with 1.0 µg of A, MA, MDA, MDMA and IS. Although A, MA, 
MDA and MDMA were not the standard samples in this study, generally these 
compounds were analogous to the IS samples, and could be distinguished in the 
GC–MS chromatogram. 
The electron impact mass spectra of 2C-B-TFA, 2C-B-d6-TFA, 2C-C-TFA, 
2C-C-d6-TFA, 2C-I-TFA, 2C-I-d6-TFA, 2C-T-2-TFA, 2C-T-2-d6-TFA, 2C-T-7- 
-TFA and 2C-T-7-d6 are presented in Figs. 3–7. Very high [M]+ peaks were 
observed for 2C-B-TFA, 2C-C-TFA, 2C-I-TFA, 2C-T-2-TFA and 2C-T-7-TFA at 
m/z 355, 311, 403, 337 and 351, respectively. For 2C-B-d6-TFA, 2C-C-d6-TFA, 
2C-I-d6-TFA, 2C-T-2-d6-TFA and 2C-T-7-d6-TFA, very strong [M]+ peaks ap-
peared at m/z 361, 317, 409, 343 and 357, respectively. 1226 XU  et al. 
 
Fig. 2. Total ion chromatography (time in min). The concentrations of 
the analytes were 0.50 µg mL-1. 
TABLE I. Retention times and ions monitored for GC/MS analysis 
Compound  Retention time, min  Ions monitoreda (relative intensity, %) 
2C-C-d6 5.98  204, 191 (69.4), 317 (67.8) 
2C-C 5.99  198, 185 (78.7), 311 (74.2) 
2C-B-d6 6.26  248, 361 (76.3), 235 (61.2) 
2C-B 6.27  242, 355 (75.6), 229 (77.7) 
2C-I-d6 6.61  409, 296 (80.9), 283 (50.8) 
2C-I 6.62  403, 290 (85.6), 277 (53.1) 
2C-T-2-d6 6.66  217, 343 (82.6), 230 (26.5) 
2C-T-2 6.67  211, 337 (74.1), 224 (23.8) 
2C-T-7-d6 6.93  231, 357 (78.1), 244 (23.5) 
2C-T-7 6.94  225, 351 (89.6), 238 (23.9) 
AMP 3.64  140, 118 (91.9), 91 (40.6) 
MA 4.14  154, 118 (29.9), 110 (22.7) 
MDA 5.05  162, 275 (49.0), 135 (234.4) 
MDMA  5.51 154, 162 (78.4), 135 (56.1) 
aQuantification ions underlined 
The EI mass spectrum of 2C-B-d6-TFA (Fig. 3) has a base peak ion at m/z 
248. This odd electron ion was formed by a McLafferty rearrangement to elimi-
nate trifluoroacetamide (Scheme 1). The ion m/z 235 was also generated by eli-
minating an N-ethylidene-2,2,2-trifluoroacetamide from the molecular ion m/z 361. 
The ion m/z 203 was formed from the ion m/z 235 by the well-known specific 
six-center H-rearrangement of a γ-D-atom of the methoxy-d3 (OCD3) side chain 
to the benzylic part, eliminating neutral formaldehyde-d2 (CD2O). This rearran-
gement was proven by comparing the mass spectrum of 2C-B-TFA and 2C-B-d6-
-TFA (Fig. 3), i.e., the ion m/z 199 corresponds to ion m/z 203 in 2C-B-d6-TFA 
and the ion m/z 203 has four deuterium atoms. 2C-B-d6-TFA contains a bromine 
and thus the ions m/z 361, 248, 235 and 203 always have corresponding isotopic 
ions m/z 363, 251, 237 and 205. The ion m/z 151 was generated by eliminating a   DIMETHOXYPHENETHYLAMINE DERIVATIVES IN URINE  1227 
bromomethane (BrCD3) from the molecular ion m/z 248. Compounds 2C-B, 2C-C, 
2C-I, 2C-C-d6 and 2C-I-d6 have the same fragmentation pathway, and their cor-
responding mass spectra are shown in Fig. 3–5. 
a) 
b) 
Fig. 3. The mass spectra of 
TFA derivatives of 2C-B (a) 
and 2C-B-d6 (b). 
 
Scheme 1. Spectral interpretation of N-[2-(4-bromo-2,5-dimethoxyphenyl)ethyl]- 
-2,2,2-trifluoroacetamide-d6 (2C-B-d6-TFA). 1228 XU  et al. 
a) 
b) 
Fig. 4. The mass spectra of 
TFA derivatives of 2C-C (a) 
and 2C-C-d6 (b). 
a) 
b) 
Fig. 5. The mass spectra of 
TFA derivatives of 2C-I (a) 
and 2C-I-d6 (b).   DIMETHOXYPHENETHYLAMINE DERIVATIVES IN URINE  1229 
The EI mass spectrum of 2C-T-2-d6-TFA (Fig. 6) has a base peak ion at m/z 
217. The ion m/z 217 was generated by eliminating N-ethylidene-2,2,2-trifluoro-
acetamide from the molecular ion m/z 343. This odd electron ion m/z 230 was 
formed by a McLafferty rearrangement to eliminate a trifluoroacetamide (Scheme 2). 
The ion m/z 185 was formed from the ion m/z 217 by the well-known specific 
six-center H-rearrangement of a γ-D-atom of the methoxy-d3 (OCD3) side chain 
to the benzylic part, eliminating neutral formaldehyde-d2 (CD2O). This rearran-
gement was proven by comparing the mass spectrum of 2C-T-2-TFA and 2C-T- 
-2-d6-TFA (Fig. 6), i.e., the ion m/z 181 corresponds to ion m/z 185 in 2C-T-2-d6-
-TFA, and ion m/z 185 has four deuterium atoms. The ion m/z 157 was generated 
by eliminating an ethylene (CH2=CH2) from the molecular ion m/z 185. Com-
pounds 2C-T-2, 2C-T-7 and 2C-T-7-d6 have the same fragmentation pathway 
and their corresponding mass spectra are shown in Figs. 6 and 7. 
a) 
b) 
Fig. 6. The mass spectra of 
TFA derivatives of 2C-T-2 
(a) and 2C-T-2-d6 (b). 
The extraction and derivatization were performed using ethyl acetate as sol-
vent. Due to the need to heat for derivatization, a solvent with boiling point 
above 60 °C was selected. The boiling point of ethyl acetate is 77 °C. The deriva-
tization time (30 min) and temperature (60 °C) were selected, because these deri-
vatization conditions are well established.16 
The linearity of the quantification method was determined using calibration 
standards at 0, 50, 100, 500, 1000, 2000 ng of analyte. The selected ion moni-
toring (SIM) mode was employed throughout the study. Linear regression of the  1230 XU  et al. 
 
Scheme 2. Spectral interprettation of N-[2-(4-ethylsulfanyl-2,5-dimethoxyphenyl) 
ethyl]-2,2,2-trifluoroacetamide-d6 (2C-2-T-d6-TFA). 
a) 
b) 
Fig. 7. The mass spectra of 
TFA derivatives of 2C-T-7 
(a) and 2C-T-7-d6 (b).   DIMETHOXYPHENETHYLAMINE DERIVATIVES IN URINE  1231 
calibration curves gave r2 values between 0.9946 and 0.9999, with most values  
> 0.9990. The limit of detection (LOD) was defined as the signal noise ratio, 
equal to 3. The LOD values of the target compounds are given in Table II, from 
which it can be seen that the calibration curves for the studied compounds gave 
excellent straight lines over the range of 0–2000 ng mL–1. Thus, excellent ac-
curacy and precision could be obtained by this method. 
Table II. Linear regression of the calibration curves 
Compound  Coefficient of 
correlation (r2)  Regression line  LOD (S/N = 3) 
ng mL-1 
2C-C 0.9998  y = 0.0026x – 0.0084  5.1 
2C-B 0.9946  y = 0.0023x + 0.0259  8.0 
2C-I 0.9999  y = 0.0015x – 0.0061  6.7 
2C-T-2 0.9991  y = 0.0018x – 0.0128  1.6 
2C-T-7 0.9999  y = 0.0015x – 0.0061  2.9 
CONCLUSIONS 
This study demonstrates the applications of 2C-B-d6, 2C-C-d6, 2C-I-d6, 
2C-T-2-d6 and 2C-T-7-d6 as internal standards in GC–MS. Although the GC re-
tention times of the five sets of labeled and unlabeled compounds vary very little 
(0.01 min), quantification by MS with the selected ion monitoring (SIM) tech-
nique enhances the performance of the quantitative analysis. Therefore, five de-
uterium-labeled compounds possess the potential to be used as the internal 
standard for GC–MS analysis. 
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ПРИМЕНОМ ДЕУТЕРИСАНИХ ИНТЕРНИХ СТАНДАРДА 
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Hualien 970 и 3Department of Laboratory Medicine and Biotechnology, Tzu Chi University, Hualien 970, Taiwan, R. O. C. 
У  форензичкој  анализи  примена  гасне  хроматографије  са  масеном  спектрометријом 
(GC–MS) је све већа. Употреба обележених стандарда може побољшати перформансе кван-
титативне хемијске анализе, повећањем тачности и прецизности одређивања методом GC–MS. 
Синтетисана је серија деутерисаних интерних стандарда, која одговара 2С серији деривата 
фенетиламина, укључујући 4-бром-2,5-диметоксифенетиламин-d6 (2C-B), 4-хлор-2,5-димето-
ксифенетиламин-d6  (2C-C), 4-јод-2,5-диметокси-фенетиламин-d6  (2C-I), 4-етилтио-2,5-димет-
окси-фенетиламин-d6 (2C-T-2) и 2,5-диметокси-4-n-пропилтиофенетиламин-d6 (2C-T-7). Деу-
терисана једињења су коришћена у анализи одговарајућих необележених једињења у узор-1232 XU  et al. 
цима урина. Анализа је изведена применом GC–MS у SIM (техника мониторинга одабраних 
јона) моду, при чему су добијани аналитички поуздани резултати. 
(Примљено 4. фебруара, ревидирано 21. јуна 2008) 
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